Cargando…

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo

Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are found in a somatic mosaic fashion in patients with multiple enchondromas. Enchondromas are benign cartilaginous tumors arising in the medulla of bone. The mutant IDH1/2 causes elevated levels of D-2-hydroxyglutarate (D-2-HG). Mesenchymal st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suijker, Johnny, Baelde, Hans J., Roelofs, Helene, Cleton-Jansen, Anne-Marie, Bovée, Judith V.M.G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper: Pathology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558118/ https://www.ncbi.nlm.nih.gov/pubmed/26046462

Ejemplares similares

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
por: Hujber, Zoltán, et al.
Publicado: (2017)

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-Hydroxyglutarate
por: Fan, Jing, et al.
Publicado: (2014)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
por: Carbonneau, Mélissa, et al.
Publicado: (2016)

The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites
por: Hariharan, Vivek A., et al.
Publicado: (2017)

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
por: Li, Luyuan, et al.
Publicado: (2015)

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
por: Suijker, Johnny, et al.
Publicado: (2015)

Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
por: Shim, Eun-Hee, et al.
Publicado: (2015)

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite
por: Berger, Raffaela S., et al.
Publicado: (2021)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis
por: Pickard, Amanda J., et al.
Publicado: (2016)

Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate and promotes histone methylation
por: Fan, Jing, et al.
Publicado: (2014)

The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
por: Rakheja, Dinesh, et al.
Publicado: (2013)

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
por: Akbay, Esra A., et al.
Publicado: (2014)

Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases
por: Evans, Brad, et al.
Publicado: (2015)

Imaging 2-hydroxyglutarate and other brain oncometabolites pertinent to critical genomic alterations in brain tumors
por: Thomas, Teena, et al.
Publicado: (2023)

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
por: Cleven, Arjen H. G., et al.
Publicado: (2017)

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
por: Richardson, Leland G., et al.
Publicado: (2019)

Renal oncometabolite L-2-hydroxyglutarate imposes a block in kidney tubulogenesis: Evidence for an epigenetic basis for the L-2HG-induced impairment of differentiation
por: Taub, Mary, et al.
Publicado: (2022)

The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation
por: Liu, Lizhen, et al.
Publicado: (2021)

Oncometabolite D-2-hydroxyglutarate—dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia
por: Zhu, Xinting, et al.
Publicado: (2023)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
por: Viswanath, Pavithra, et al.
Publicado: (2018)

Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
por: Longuespée, Rémi, et al.
Publicado: (2018)

Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases
por: Janke, Ryan, et al.
Publicado: (2017)

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
por: Ma, Shenghong, et al.
Publicado: (2015)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Andronesi, Ovidiu C., et al.
Publicado: (2018)

Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas
por: Autry, Adam W., et al.
Publicado: (2022)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model
por: Wang, Fang, et al.
Publicado: (2016)

Metabolomic analysis identifies differentially produced oral metabolites, including the oncometabolite 2-hydroxyglutarate, in patients with head and neck squamous cell carcinoma
por: Mukherjee, Pranab K., et al.
Publicado: (2016)

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells
por: Chen, Jing-Yi, et al.
Publicado: (2016)

Accumulation of oncometabolite D-2-Hydroxyglutarate by SLC25A1 inhibition: A metabolic strategy for induction of HR-ness and radiosensitivity
por: Xiang, Kexu, et al.
Publicado: (2022)

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

A Drosophila model of combined D-2- and L-2-hydroxyglutaric aciduria reveals a mechanism linking mitochondrial citrate export with oncometabolite accumulation
por: Li, Hongde, et al.
Publicado: (2018)

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
por: Kotredes, Kevin P., et al.
Publicado: (2019)

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
por: Chittaranjan, Suganthi, et al.
Publicado: (2014)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
por: Leather, Thomas, et al.
Publicado: (2017)

Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate
por: Sesanto, Rae, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f5i0hc52bh4056m1vk049808gl